AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17545883 — intervention group
Group type: COMPARATOR
Intervention: TRAD (four sets of six reps at 52.5% 1RM)
Number of subjects: 22
Study 15746299 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of bicycle training (up to 45 min at 80% peak heart rate, 3-4 days/week)
Number of subjects: 142
Study 15746299 — intervention group
Group type: COMPARATOR
Intervention: Baseline (before training)
Number of subjects: 142
Study 12006305 — intervention group
Group type: EXPERIMENTAL
Intervention: integrated care pathways management
Number of subjects: 76
Study 12006305 — intervention group
Group type: COMPARATOR
Intervention: conventional multidisciplinary care
Number of subjects: 76
Study 11120696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 14
Study 11120696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8858222 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose 12-15 mmol/l)
Number of subjects: 8
Study 1634643 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (20 mg isosorbide-5-mononitrate)
Number of subjects: 24
Study 1634643 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (20 mg isosorbide-5-mononitrate)
Number of subjects: 24
Study 6519164 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (12 to 192 mg)
Number of subjects: 10
Study 31087135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 76
Study 31087135 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus cisplatin (PF)
Number of subjects: 76
Study 30373488 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who consented to participate in the RCT (n=713)
Number of subjects: 1338
Study 30373488 — intervention group
Group type: COMPARATOR
Intervention: Patients who declined to participate in the RCT (n=625)
Number of subjects: 1338
Study 28003206 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc increase from 6 mg Zn/d to 10 mg Zn/d for 4 weeks
Number of subjects: 18
Study 24870622 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 87
Study 24870622 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 87
Study 24870622 — intervention group
Group type: COMPARATOR
Intervention: Un‐paced breathing
Number of subjects: 87
Study 24870622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 87
Study 24232364 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted movement and muscle vibration combined with torque biofeedback
Number of subjects: 43
Study 24232364 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted movement and muscle vibration combined with EMG biofeedback
Number of subjects: 43
Study 24232364 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted movement and muscle vibration
Number of subjects: 43
Study 24232364 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 21401921 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 75 mg per day) with psychotherapy (n = 30)
Number of subjects: 90
Study 21401921 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy alone (n = 60)
Number of subjects: 90
Study 18492379 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium suppository 100 mg (Voltarol) at the end of oocyte retrieval
Number of subjects: 381
Study 18492379 — intervention group
Group type: COMPARATOR
Intervention: nothing (control group)
Number of subjects: 381
Study 17176187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy with family-focused techniques
Number of subjects: 63
Study 17176187 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional family therapy with adolescent-focused techniques
Number of subjects: 63
Study 14580004 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT50 (50 microg/actuation)
Number of subjects: 41
Study 14580004 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT100 (100 microg/actuation)
Number of subjects: 41
Study 14580004 — intervention group
Group type: COMPARATOR
Intervention: MDI100 (100 microg/actuation)
Number of subjects: 41
Study 10883827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescribed according to culture and sensitivity (Group A)
Number of subjects: 110
Study 10883827 — intervention group
Group type: COMPARATOR
Intervention: Broad-spectrum antimicrobial (co-trimoxazole) prescribed blindly (Group B)
Number of subjects: 110
Study 9369053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for 6 hours
Number of subjects: 617
Study 9369053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for 8 hours
Number of subjects: 617
Study 9369053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for longer than 3 hours
Number of subjects: 617
Study 9369053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine containing adhesive tape (LT) applied for 12 hours
Number of subjects: 617
Study 9369053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine tape)
Number of subjects: 617
Study 8404800 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received a compliment and a self-descriptive questionnaire before receiving a mailed brochure about the bone-marrow registry.
Number of subjects: 0
Study 8404800 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the mailed brochure.
Number of subjects: 0
Study 8404800 — intervention group
Group type: COMPARATOR
Intervention: No mailing group (control).
Number of subjects: 0
Study 3535860 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of lignocaine-prilocaine cream (EMLA)
Number of subjects: 60
Study 3535860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29705459 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 40
Study 29705459 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 26522233 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free bread (GFB)
Number of subjects: 12
Study 26522233 — intervention group
Group type: EXPERIMENTAL
Intervention: Added gluten content bread (AGCB)
Number of subjects: 12
Study 26522233 — intervention group
Group type: COMPARATOR
Intervention: Normal gluten content bread (NGCB)
Number of subjects: 12
Study 24685369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra‐MIS (1mm incision)
Number of subjects: 40
Study 24685369 — intervention group
Group type: COMPARATOR
Intervention: Mini‐OCTR (2 cm incision)
Number of subjects: 40
Study 24201696 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg perindopril daily for 20 weeks
Number of subjects: 170
Study 24201696 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training + ACEi
Number of subjects: 170
Study 24201696 — intervention group
Group type: COMPARATOR
Intervention: Exercise training only
Number of subjects: 170
Study 20220293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (im TU)
Number of subjects: 52
Study 20220293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (oral TU)
Number of subjects: 52
Study 20220293 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo gel (P)
Number of subjects: 52
Study 17575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program (6 workshops of 3 hours each following a 2.5-day basic training)
Number of subjects: 0
Study 17575569 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study 16402614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden Markov models (HMMs) with five to ten hidden states for blood pressure variability classification
Number of subjects: 90
Study 16402614 — intervention group
Group type: EXPERIMENTAL
Intervention: Hidden Markov models (HMMs) with fifteen hidden states for RR-based classification
Number of subjects: 90
Study 16402614 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy disorders (preeclampsia and pregnancy-induced hypertension)
Number of subjects: 90
Study 14721993 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary epicardial pacing wires (PWs)
Number of subjects: 197
Study 14721993 — intervention group
Group type: COMPARATOR
Intervention: No pacing wires (PWs)
Number of subjects: 197
Study 11016387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation therapy
Number of subjects: 57
Study 11016387 — intervention group
Group type: COMPARATOR
Intervention: Intercostal application of local anesthetic agents (Control)
Number of subjects: 57
Study 8879616 — intervention group
Group type: EXPERIMENTAL
Intervention: Purged PBPC (75 micrograms/ml of ether lipid for 4 h at 37 degrees C)
Number of subjects: 37
Study 8879616 — intervention group
Group type: COMPARATOR
Intervention: Non-purged PBPC
Number of subjects: 37
Study 8879616 — intervention group
Group type: EXPERIMENTAL
Intervention: Purged PBPC
Number of subjects: 37
Study 7868698 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattentive (I)
Number of subjects: 116
Study 7868698 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattentive and Impulsive (II)
Number of subjects: 116
Study 7868698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive and Impulsive (HII)
Number of subjects: 116
Study 7868698 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 116
Study 3340909 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 16
Study 3340909 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 16
Study 29978597 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% taurolidine
Number of subjects: 105
Study 29978597 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 105
Study 27980016 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher temperature
Number of subjects: 981
Study 27980016 — intervention group
Group type: COMPARATOR
Intervention: Precipitation, humidity, wind speed, wind gust, wind direction, air pressure
Number of subjects: 981
Study 28500216 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 2280
Study 28500216 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 2280
Study 28500216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2280
Study 28500216 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin at year 8
Number of subjects: 2280
Study 28500216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative metformin exposure
Number of subjects: 2280
Study 23725995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with implantable cardioverter defibrillator (ICD), n = 132
Number of subjects: 132
Study 23725995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with ICD, n = 132
Number of subjects: 132
Study 23725995 — intervention group
Group type: COMPARATOR
Intervention: Control group (ICD-only), n = 87
Number of subjects: 132
Study 21418447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (cereal-lentil mixture providing 930 kcal and multivitamin micronutrient supplement)
Number of subjects: 103
Study 21418447 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 103
Study 19655825 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC plus atorvastatin 40 mg/day and ezetimibe 10 mg/day
Number of subjects: 34
Study 19655825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18247250 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Implementation (TI) methods in a rehabilitation team‐training intervention
Number of subjects: 29
Study 14760792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg/day
Number of subjects: 212
Study 14760792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 1.5 mg/day
Number of subjects: 212
Study 14760792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 11772141 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 11772141 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus leucovorin
Number of subjects: 0
Study 9661016 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 50 mg b.i.d. for 5 days
Number of subjects: 6
Study 9661016 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 100 mg b.i.d. for 5 days
Number of subjects: 6
Study 9661016 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (TP) 200 mg b.i.d. for 9 days
Number of subjects: 6
Study 7595905 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan monotherapy
Number of subjects: 12
Study 7595905 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-HCTZ combination therapy
Number of subjects: 12
Study 7595905 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (both monotherapy and combination therapy)
Number of subjects: 12
Study 7595905 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12
Study 2204855 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser alone
Number of subjects: 12
Study 2204855 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser pretreatment followed by Nd:YAG laser
Number of subjects: 12
Study 645143 — intervention group
Group type: EXPERIMENTAL
Intervention: haemiton compositum
Number of subjects: 14
Study 31612482 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 28 mg
Number of subjects: 475
Study 31612482 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 475
Study 31612482 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 475
Study 31612482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study 29200836 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive stimulation (CCS) program
Number of subjects: 19
Study 29200836 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive engagement (CCE) program
Number of subjects: 19
Study 25596848 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed during working hours for 5×10 minutes per week
Number of subjects: 200
Study 25596848 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME) performed during leisure time for 5×10 minutes per week
Number of subjects: 200
Study 25596848 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK)
Number of subjects: 200
Study 23130781 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus defibrillator device implantation
Number of subjects: 406
Study 23130781 — intervention group
Group type: EXPERIMENTAL
Intervention: AF history
Number of subjects: 406
Study 23130781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent or new atrial arrhythmias
Number of subjects: 406
Study 21514032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone once daily for 14 days after insemination
Number of subjects: 71
Study 21514032 — intervention group
Group type: COMPARATOR
Intervention: No progesterone (unsupported cycles)
Number of subjects: 71
Study 18444848 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg) once daily for 5-14 days
Number of subjects: 834
Study 18444848 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g) once daily for 5-14 days
Number of subjects: 834
Study 18444848 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg) once daily for 5-14 days with prior effective therapy
Number of subjects: 834
Study 18444848 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g) once daily for 5-14 days with prior effective therapy
Number of subjects: 834
Study 16596465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose risperidone
Number of subjects: 40
Study 12691439 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation resonator sensor (ARS) for measuring IOP
Number of subjects: 180
Study 12691439 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned spherical contact surface of the sensor probe
Number of subjects: 180
Study 11094588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.0 mg kg-1
Number of subjects: 602
Study 11094588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium 2.5 mg kg-1
Number of subjects: 602
Study 11094588 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg kg-1
Number of subjects: 602
Study 11094588 — intervention group
Group type: COMPARATOR
Intervention: Rapacuronium 2.0 mg kg-1 vs Succinylcholine
Number of subjects: 602
Study 11094588 — intervention group
Group type: COMPARATOR
Intervention: Rapacuronium 2.5 mg kg-1 vs Succinylcholine
Number of subjects: 602
Study 11094588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium (both doses)
Number of subjects: 602
Study 11094588 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 602
Study 1723288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early consolidation therapy with 6 courses of CVP (cyclophosphamide, vincristine, prednisone) given monthly
Number of subjects: 81
Study 1723288 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with cyclophosphamide and prednisone given every 6 weeks for 2 years
Number of subjects: 81
Study 1723288 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (observation)
Number of subjects: 81
Study 7468581 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in three days
Number of subjects: 0
Study 7468581 — intervention group
Group type: COMPARATOR
Intervention: Four doses of human diploid cell strains rabies vaccine (HDCV) administered in 14 days
Number of subjects: 0
Study 31998994 — intervention group
Group type: EXPERIMENTAL
Intervention: Count-only approaches
Number of subjects: 0
Study 31998994 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative control counts
Number of subjects: 0
Study 31998994 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard estimators based on CRTs with negative controls
Number of subjects: 0
Study 30558972 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) with laparoscopic interval debulking surgery (IDS); 51 patients underwent laparoscopic IDS, 25 had laparoscopic optimal cytoreduction (76% R0).
Number of subjects: 282
Study 30558972 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complexity score (SCS) ≥ 3; in multivariate analyses, SCS ≥ 3 was significantly predictive of worse disease-specific overall survival (DSS) (p = 0.04).
Number of subjects: 282
Study 30558972 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 75+; in multivariate analyses, age 75+ was significantly predictive of worse DSS (p ≤ 0.001).
Number of subjects: 282
Study 30558972 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual disease >1 cm; in multivariate analyses, residual disease >1 cm was significantly predictive of worse DSS (p = 0.03).
Number of subjects: 282
Study 30558972 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal debulking defined as R0; in the R0 cohort, SCS did not significantly predict DSS.
Number of subjects: 282
Study 29944894 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed training with real-time feedback
Number of subjects: 87
Study 29944894 — intervention group
Group type: COMPARATOR
Intervention: Conventional BLS training (control)
Number of subjects: 87
Study 27347999 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso HMS
Number of subjects: 10
Study 27347999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HMS
Number of subjects: 10
Study 27347999 — intervention group
Group type: COMPARATOR
Intervention: G
Number of subjects: 10
Study 24192642 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 26
Study 24192642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 22118999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tropicamide eye drops
Number of subjects: 471
Study 22118999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 471
Study 20388753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV (mean inspiratory pressure of 28.6+/−1.9 mbar)
Number of subjects: 17
Study 20388753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity NPPV
Number of subjects: 17
Study 20388753 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity NPPV (mean inspiratory pressure of 14.6+/−0.8 mbar)
Number of subjects: 17
Study 17486918 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of neuromuscular blocking drug (rocuronium) at induction
Number of subjects: 0
Study 17486918 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of neuromuscular blocking drugs
Number of subjects: 0
Study 15606435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg single oral dose)
Number of subjects: 18
Study 15606435 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9 polymorphism
Number of subjects: 18
Study 12199005 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 19
Study 9988249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutramigen
Number of subjects: 60
Study 9988249 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfamil
Number of subjects: 60
Study 9988249 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 60
Study 7777246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron administered in group A: 8 mg IV infusion over 10 min before CDDP, followed by 8 mg orally every 8 h for 3 days.
Number of subjects: 80
Study 7777246 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron administered in group B: six intravenous doses every 6 h starting 12.5 h before cisplatin, followed by 8 mg orally every 6 h for 3 days.
Number of subjects: 80
Study 2225876 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg urapidil infusion
Number of subjects: 7
Study 2225876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7074752 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise program
Number of subjects: 42